345-30-2Relevant academic research and scientific papers
BENZIMIDAZOLE DERIVATIVES
-
Page/Page column 53; 76, (2021/06/26)
The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.
INHIBITORS OF TRKA KINASE
-
Page/Page column 36, (2016/08/17)
The present invention is directed to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA): Formula (I) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof
Acetamidoarenediazonium Salts: Opportunities for Multiple Arene Functionalization
Schmidt, Bernd,Elizarov, Nelli,Riemer, Nastja,H?lter, Frank
, p. 5826 - 5841 (2015/09/15)
Unlike their ortho counterparts, meta- and para-acetamidoanilines can be converted into the corresponding acetamidoarenediazonium salts. These offer various opportunities for multiple Pd-catalyzed arene functionalization reactions, such as Matsuda-Heck-, Suzuki-Miyaura- or Fujiwara-Moritani couplings. Acetamidoarenediazonium salts, accessible from simple acetamidoanilines, are starting points for multiple Pd-catalyzed arene functionalization reactions.
HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS
-
, (2008/06/13)
Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
